Human papillomaviruses (HPVs) cause approximately 5% of cancer cases worldwide.
Persistent infection with high-risk HPV (HR-HPV) types (HPV16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 70, 73, 82) is associated with ~94% of anal cancers, ~63% of penile cancers, ~74% of vaginal cancers, ~5–20% of head & neck squamous cell carcinomas, and nearly all cases of cervical cancers.
There are some prophylactic vaccines have been approved to protect against certain types of HPV infections. The vaccines are composed of virus-like particles (VLPs) derived from HPV major capsid protein (L1).
>95% as determined by SDS-PAGE
< 20 EU per mL protein as determined by the LAL method.
|Catalogue No.||Product description||Application||Specificity|
|68009-MM01||HPV16 L1 Antibody (Conformational Antibody), Mouse MAb||ELISA, IHC-P, FCM, ICC/IF, IF, IP||HPV16 capsid L1|
• Zhai et al.A Novel Candidate MS2 Phage VLP Vaccine Displaying a tandem HPV L2 Peptide offers Similar Protection in Mice to Gardasil-9.Antiviral Res. 2017 November ; 147: 116–123
• A. Touzeè et al. Production of recombinant virus-like particles from human papillomavirus types 6 and 11, and study of serological reactivities between HPV 6, 11, 16 and 45 by ELISA: implications for papillomavirus prevention and detection. FEMS Microbiology Letters 160 (1998) 111-118
• Stanley M1.HPV vaccination in boys and men.Hum Vaccin Immunother. 2014;10(7):2109-11.
• Stanley MA1, Sterling JC.Host responses to infection with human papillomavirus.Curr Probl Dermatol. 2014;45:58-74.